Profile data is unavailable for this security.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beijing Tiantan Biological Products Corp | 5.23bn | 1.27bn | 42.93bn | 4.86k | 33.69 | 4.03 | -- | 8.21 | 0.6444 | 0.6444 | 2.65 | 5.38 | 0.3471 | 0.8137 | 198.92 | 1,076,946.00 | 11.47 | 11.71 | 16.75 | 16.50 | 54.23 | 49.39 | 33.05 | 27.71 | 3.31 | -- | 0.0046 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 76.39bn | 3.42bn | 43.39bn | 28.05k | 13.41 | 1.27 | -- | 0.568 | 2.11 | 2.11 | 46.99 | 22.28 | 0.9946 | 6.07 | 4.60 | 2,723,576.00 | 4.71 | 5.90 | 8.93 | 12.40 | 16.55 | 18.70 | 4.74 | 5.56 | 1.15 | -- | 0.317 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
Beijing Tongrentang Co Ltd | 17.96bn | 1.63bn | 54.93bn | 16.78k | 33.73 | 4.23 | -- | 3.06 | 1.19 | 1.19 | 13.09 | 9.46 | 0.5912 | 1.08 | 11.14 | 1,070,467.00 | 7.88 | 8.20 | 15.63 | 16.17 | 44.48 | 46.59 | 13.33 | 13.33 | 1.58 | -- | 0.1765 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
Shanghai Fosun Pharmaceutical (Group) | 41.61bn | 2.11bn | 64.05bn | 40.37k | 33.85 | 1.51 | -- | 1.54 | 0.7883 | 0.7883 | 15.54 | 17.71 | 0.3682 | 2.86 | 5.10 | 1,030,748.00 | 2.44 | 4.31 | 4.18 | 7.01 | 47.10 | 50.71 | 6.63 | 10.65 | 0.7221 | -- | 0.3755 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
Sichuan Biokin Pharmaceutical Co Ltd | 5.85bn | 3.80bn | 71.75bn | 2.09k | 18.88 | 16.92 | -- | 12.27 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
Beijing Wantai Biolog Pha Ent Co Ltd | 2.49bn | -294.04m | 90.95bn | 3.84k | -- | 7.32 | -- | 36.53 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
Data as of Nov 01 2024. Currency figures normalised to Sichuan Biokin Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 6.74m | 7.45% |
China Asset Management Co., Ltd.as of 30 Jun 2024 | 5.42m | 5.99% |
GF Fund Management Co., Ltd.as of 30 Jun 2024 | 5.21m | 5.76% |
E Fund Management Co., Ltd.as of 30 Jun 2024 | 4.43m | 4.90% |
China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.24m | 2.47% |
JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2024 | 1.42m | 1.57% |
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 1.15m | 1.27% |
Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.09m | 1.20% |
Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 790.41k | 0.87% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 683.64k | 0.76% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.